Australia - English - Department of Health (Therapeutic Goods Administration)

therabody australia pty ltd - 44768 - compression system stocking/sleeve/suit, multi-chamber, reusable - the recovery pump powered inflatable massager is indicated for the temporary relief of minor aches & pains and for temporary increase in circulation in the treated areas of people who are in good health. the recovery pump simulates the kneading & stroking of tissues by an inflatable garment

Australia - English - Department of Health (Therapeutic Goods Administration)

therabody australia pty ltd - 46573 - physical therapy electrical stimulation system, battery-powered - a battery-powered device used to apply various modes of electrical stimulation transcutaneously to treat/prevent neuromuscular symptoms and disorders typically as a form of physical therapy. it is used to prevent muscle atrophy, for muscle re-education, to relax muscle spasms causing pain, to improve blood circulation, and/or to maintain or increase range of motion. stimulation can be also applied to healthy muscles where electrical stimulation can be used as a form of training.

Australia - English - Department of Health (Therapeutic Goods Administration)

therabody australia pty ltd - 62202 - blue/red/infrared phototherapy lamp - the theraface mask is intended to provide phototherapy treatments through the use of blue/red/infrared light to treat full-face wrinkles and mild to moderate inflammatory acne. it also has a vibration mode to help relax the skin.

United States - English - NLM (National Library of Medicine)

wessco international - sodium monofluorophosphate (unii: c810jcz56q) (fluoride ion - unii:q80vpu408o) - helps protect against cavities

United States - English - NLM (National Library of Medicine)

wessco international - sodium monofluorophosphate (unii: c810jcz56q) (fluoride ion - unii:q80vpu408o) - helps protect against cavities

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - estradiol, quantity: 0.78 mg (equivalent: estradiol, qty 50 microgram/24 h; equivalent: estradiol hemihydrate, qty 0.806 mg) - drug delivery system, transdermal - excipient ingredients: povidone; dipropylene glycol; oleyl alcohol; ethyl acetate; toluene; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; ethylene/vinyl acetate copolymer; 1,1-dichloroethylene, chloroethylene polymer; polyethylene; sodium carbonate; simethicone; dimeticone; xylene; cyclomethicone - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - estradiol, quantity: 0.78 mg (equivalent: estradiol, qty 50 microgram/24 h; equivalent: estradiol hemihydrate, qty 0.806 mg) - drug delivery system, transdermal - excipient ingredients: povidone; dipropylene glycol; oleyl alcohol; polyethylene terephthalate; polyvinylidene flouride; ethyl acetate; simethicone; dimeticone; xylene; cyclomethicone; toluene; acrylates/va copolymer; ethylene/vinyl acetate copolymer; 1,1-dichloroethylene, chloroethylene polymer; polyethylene; sodium carbonate - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - norethisterone acetate, quantity: 4.8 mg (equivalent: estradiol hemihydrate, qty 0.806 mg; equivalent: norethisterone acetate, qty 250 microgram/24 h); estradiol, quantity: 0.512 mg (equivalent: estradiol, qty 50 microgram/24 h; equivalent: estradiol hemihydrate, qty 0.529 mg) - drug delivery system, transdermal - excipient ingredients: oleic acid; povidone; dipropylene glycol; polytrimethylhydrosilylsiloxane; xylene; ammonia; toluene; 1,1,1-trimethyl-n-(trimethylsilyl)silanamine; dimeticonol; polyethylene terephthalate; polyvinylidene flouride; ethyl acetate; ethanol; acrylates/va copolymer; ethylene/vinyl acetate copolymer - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - norethisterone acetate, quantity: 2.7 mg (equivalent: estradiol hemihydrate, qty 0.806 mg; equivalent: norethisterone acetate, qty 140 microgram/24 h); estradiol, quantity: 0.62 mg (equivalent: estradiol, qty 50 microgram/24 h; equivalent: estradiol hemihydrate, qty 0.64 mg) - drug delivery system, transdermal - excipient ingredients: povidone; oleic acid; dipropylene glycol; polytrimethylhydrosilylsiloxane; xylene; ammonia; toluene; 1,1,1-trimethyl-n-(trimethylsilyl)silanamine; dimeticonol; ethyl acetate; ethanol; acrylates/va copolymer; polyethylene terephthalate; polyvinylidene flouride; ethylene/vinyl acetate copolymer - for the short-term treatment of symptoms of oestrogen deficiency in menopausal women who have an intact uterus. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase the risk of breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

catalent australia pty ltd - royal jelly -